In preclinical models of pancreatic cancer, treatment with GNE-140 (3), a potent LDH-A inhibitor, resulted in mitochondrial compensation, mediated by the activation of the AMPK-mTOR-S6K pathway. This evidence concerns the gene MTOR and pancreatic neoplasm.